Catecholaminergic polymorphic ventricular tachycardia (CPVT) carries increased risk of ventricular arrhythmias due to altered Ca2+ regulation associated with mutations in the ryanodine receptor (RyR2). Here, RYR2 is linked to catecholaminergic polymorphic ventricular tachycardia.